Home / Inspections / 1173461

FDA Inspection 1173461 — Cadila Pharmaceuticals Limited

Cadila Pharmaceuticals Limited — FEI 3007684569

The FDA completed an inspection of Cadila Pharmaceuticals Limited on June 17, 2022 in Ahmedabad. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
June 17, 2022
Fiscal Year
2022
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Ahmedabad (India)

Additional Details

Clinical BA/BE

Facility

Other inspections at this facility

  • 1293740 (NAI Fri Sep 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1205061 (NAI Fri Apr 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1120482 (NAI Fri Feb 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1052117 (VAI Thu May 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 929697 (VAI Fri May 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time))

FDA data resources